He started his research career at Synthelabo and worked subsequently at Reckitt & Coleman, Glaxo, and Rhone-Poulenc  Rorer (later Aventis). Besides having authored some 70 peer reviewed publications and being an inventor on 19 patent applications, Alan has taken several compounds into clinical development and market launch. In his last three years at Aventis Alan was primarily involved in business development and secured/managed several biotech research collaborations. With the closure of Aventis’s Dagenham site Alan joined with a group of peers to start Argenta, where he was Director of Business Development and Director of Therapeutics.  He was one of the key individuals to establish Argenta as a successful drug discovery CRO. Following the merger of Argenta with Etiologics he left the company and joined Daniolabs in 2005 as Head of Research. His activities there enabled the profitable VC exit from Daniolabs via a sale to Summit plc. Alan completed his degree and PhD at Aston University.